Financial Performance - In Q1 2020, the company's operating revenue was CNY 2,510,840,032.33, a decrease of 6.11% compared to the same period last year[12]. - The net profit attributable to shareholders was CNY -186,635,649.27, representing a decline of 28.58% year-on-year[12]. - The company faced challenges in sales due to the pandemic, impacting high-margin product sales and overall revenue[12]. - Net profit for Q1 2020 was -174,811,612.15, a decline of 38.23% compared to -126,462,418.82 in Q1 2019, mainly due to decreased sales of high-margin products during the pandemic[21]. - The company reported a total comprehensive loss of ¥329,804,564.61 for Q1 2020, compared to a loss of ¥661,728,834.88 in Q1 2019[46]. - Basic and diluted earnings per share for Q1 2020 were both -¥0.07, compared to -¥0.06 in Q1 2019[46]. Cash Flow - The net cash flow from operating activities improved significantly to CNY -71,626.60, a 99.96% increase compared to the previous year[12]. - Cash flow from operating activities improved significantly, with a net cash flow of -71,626.60 compared to -178,093,682.78 in the previous year, reflecting increased sales collections[21]. - Cash flow from financing activities surged by 824.40% to 303,343,378.15 from 32,814,991.23, mainly due to increased bank loans from subsidiaries[21]. - The net cash flow from operating activities for Q1 2020 was ¥53,487,760.17, a decrease of 56.8% compared to ¥123,752,804.39 in Q1 2019[60]. - Total cash inflow from operating activities was ¥645,157,652.38, down 23% from ¥837,975,928.01 in the same period last year[60]. - Cash outflow from operating activities totaled ¥591,669,892.21, a reduction of 17.2% compared to ¥714,223,123.62 in Q1 2019[60]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 12,372,197,511.26, down 1.04% from the end of the previous year[12]. - Current liabilities increased to ¥6,274,895,125.00, up 3.39% from ¥6,068,590,947.07[32]. - Total liabilities rose to ¥6,759,180,756.72, an increase of 3.05% from ¥6,559,709,513.64[34]. - The company's equity attributable to shareholders decreased to ¥5,114,936,706.67, down 6.24% from ¥5,456,565,308.41[34]. - Total liabilities amounted to approximately ¥6.56 billion, with current liabilities at ¥6.07 billion and non-current liabilities at ¥491.12 million[69]. Shareholder Information - The number of shareholders at the end of the reporting period was 161,125, with the largest shareholder holding 46.80% of the shares[17]. - Shareholders' equity decreased to ¥3,276,742,509.54 in Q1 2020 from ¥3,634,530,038.89 in Q1 2019[40]. - The total equity attributable to shareholders of the parent company is approximately ¥5.46 billion[69]. Income and Expenses - Total operating costs for Q1 2020 were ¥2,716,622,009.04, down 2.4% from ¥2,782,541,653.46 in Q1 2019[43]. - Research and development expenses for Q1 2020 were ¥26,895,395.02, slightly down from ¥27,219,513.99 in Q1 2019[43]. - The company reported a tax expense of ¥21,813,701.94 for Q1 2020, down from ¥37,662,008.79 in Q1 2019[45]. - Selling expenses decreased to approximately ¥6.06 million in Q1 2020, down 47% from ¥11.55 million in Q1 2019[51]. - The company’s financial expenses increased to approximately ¥5.55 million in Q1 2020, compared to ¥2.89 million in Q1 2019[51]. Other Financial Metrics - The weighted average return on equity decreased by 0.91 percentage points to -3.53%[12]. - The company reported a significant increase in cash and cash equivalents, with a 41.80% rise in monetary funds to CNY 957,872,414.27[19]. - Interest expenses increased by 258.18% to 26,230,839.89 from 7,323,343.81 due to higher interest costs from subsidiaries[21]. - Interest income decreased by 60.56% to 2,044,989.09 from 5,184,914.35 primarily due to a reduction in fixed deposits[21]. - The company reported an increase in investment income to approximately ¥38.25 million in Q1 2020, up from ¥26.12 million in Q1 2019[51].
哈药股份(600664) - 2020 Q1 - 季度财报